论文部分内容阅读
目的：评估哌拉西林／三唑巴坦治疗医院内获得性肺炎的疗效和安全性；获得哌拉西林／三唑巴坦对医院内获得性肺炎病原菌的药物敏感性数据。方法：采用非对照、开放性、多中心的研究方法。４４名病人参加试验，脱落２例（不良反应），男性２８例（６６． ７％），女性１４例（３３．３％），平均年龄为５７．１１±１１．９５岁。静脉滴注哌拉西林／三唑巴坦４．５ｇ，ｑ８ｈ，一般疗程为７～１０ ｄ，必要时可加用阿米卡星。结果：哌拉西林／三唑巴坦用药结束时和随访期临床有效率一样，为 ９２． ８％（３９／４２）。哌拉西林 ／三唑巴坦用后，临床症状、体征（体温、肺部罗音、胸痛、咳嗽、咳痰等）皆有明显改善（ Ｐ＜ ０． ０５），上升的血白细胞、中性粒细胞恢复至正常，胸片示病灶吸收率为７３．８％（３１／４２）。合用阿米卡星 １０例，而不良反应２例皆在合用组中，分别表现为恶心、呕吐和 ＡＳＴ、ＡＬＴ升高。 ４２名病人结束时细菌清除率为５４．８％（２３／４２），而随访期为５９．５％（２５／４２），共检出病原菌５３株，其中铜绿假单胞菌、阴沟肠杆菌、肺炎克雷伯氏菌全被清除，而哌拉西林／三唑巴坦对鲍曼氏不动杆菌、木糖氧化产碱杆菌临床清除作用差。 ３７株病原菌药敏结果显?
OBJECTIVE: To evaluate the efficacy and safety of piperacillin / tazobactam in the treatment of hospital-acquired pneumonia and to obtain drug susceptibility data of piperacillin / tazobactam to hospital-acquired pneumonia pathogens. METHODS: A non-controlled, open, multicenter approach was used. Twenty-four patients (66.3%) and 14 women (33.3%) had an average age of 57.11 ± 11.95 years. Intravenous infusion of piperacillin / tazobactam 4.5g, q8h, the general course of treatment is 7 ~ 10d, if necessary, add amikacin. Results: The clinical efficacy of piperacillin / tazobactam at the end of treatment and follow-up was 92%. 8% (39/42). Piperacillin / tazobactam, clinical symptoms and signs (body temperature, pulmonary rales, chest pain, cough, sputum, etc.) were significantly improved (P <0. 05), rising blood leukocytes, Granulocytes returned to normal, chest X-ray showed the absorption rate was 73.8% (31/42). Combination of amikacin in 10 cases, and adverse reactions in 2 cases were in the combined group, were manifested as nausea, vomiting and AST, ALT increased. At the end of 42 patients, the bacterial clearance rate was 54.8% (23/42), while the follow-up period was 59.5% (25/42). 53 pathogenic bacteria were detected, of which Pseudomonas aeruginosa, Enterobacter cloacae , Klebsiella pneumoniae were all cleared, and piperacillin / tazobactam clinical manifestations of Acinetobacter baumannii, Xylose xylolysis clinical poor. 37 strains of drug susceptibility results?